https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=14064
https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=14064
No pharmaceutical opinion available for this interaction.
Darunavir / ritonavir can inhibit the metabolism (CYP 3A4) and increase the plasma concentration of Almotriptan.
–
–
–
Possible increase of adverse effects.
Start with a small dose or reduce the dose if already used.
Adjust the dose according to tolerability and clinical efficacy.
US monograph suggests to start with a dose of 6.25 mg when co-administered with potent CYP3A4 inhibitors and not to exceed 12.5 mg QD.
They also suggest avoiding concomitant use in patients with renal or hepatic impairment.
–
Migraine symptoms and almotriptan adverse effects : chest tightness, vasoconstriction, hypertension, nausea, drowsiness and serotonin syndrome.
–
–
Ref #3121 : Coadministration of almotriptan with ketoconazole, a strong CYP3A4 inhibitor, (400 mg QD for 3 days) resulted in an increase of approximately 60% in almotriptan AUC and Cmax.